Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience

By Cristofanilli M.   Holmes F.A.   Esparza L.   Valero V.   Buzdar A.U.   Neidhart J.A.   Hortobagyi G.N.  

Breast Cancer Research and Treatment, Vol. 54, Iss. 3, 1999-04 ,pp. : 225-233

Springer Publishing Company

Access to resources Recommend Favorite

Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study

By Prince H.M.   Rischin D.   Quinn M.   Allen D.   Planner R.   Neesham D.   Gates P.   Davison J.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 216-224

Elsevier

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite

Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer

By Haas R.   Schmid H.   Hahn U.   Hohaus S.   Goldschmidt H.   Murea S.   Kaufmann M.   Wannenmacher M.   Wallwiener D.   Bastert G.   Hunstein W.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 372-378

Elsevier

Access to resources Recommend Favorite

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial

By Verrill Mark  

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 41-43

Informa Healthcare

Access to resources Recommend Favorite